Disease Landscape and Forecast Insights

The breast cancer therapy market in mainland China is one of the most dynamic in the oncology sector. Several new and emerging therapies are expected to gain approval for specific subpopulations,…

The breast cancer therapy market in mainland China is one of the most dynamic in the oncology sector. Several new and emerging therapies are expected to gain approval for specific subpopulations,…

CDK4/6 inhibitors (Pfizer’s palbociclib, Novartis’s ribociclib, and Eli Lilly’s abemaciclib) combined with endocrine therapy are central to the treatment of metastatic HR-positive / HER2-…

CDK4/6 inhibitors (Pfizer’s palbociclib, Novartis’s ribociclib, and Eli Lilly’s abemaciclib) combined with endocrine therapy are central to the treatment of metastatic HR-positive / HER2-…

The breast cancer therapy market is one of the most dynamic markets in the oncology space in mainland China. Several new and emerging therapies are set to be approved for select subpopulations;…

Clarivate Epidemiology’s coverage of breast cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of breast…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts of key breast cancer patient populations, covering 171 countries and more…

Clarivate Epidemiology’s coverage of breast cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of breast…

The treatment of metastatic triple-negative breast cancer is rapidly evolving with new combination therapies and biomarker-driven approaches. Immunotherapies such as Keytruda (Merck & Co.) have…

The breast cancer treatment landscape is rapidly evolving. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio) plus endocrine therapy are entrenched first-line…

Key benefits and uses Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand whom to position…

CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio/Verzenios) combined with endocrine therapy are central to the treatment of metastatic hormone receptor-…